Of note, Chk1/MEK1/2 inhibition also untethered Bak from Mcl-1, and triggered Bak activation in bortezomib-resistant MM cells either endogenously displaying high levels of or ectopically expressing Mcl-1. The gene discussed is MAP2K1; the disease is Miyoshi myopathy.